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What is the diagnosis of this woman with multiple respiratory infections in the previous year and a 
recent onset of progressive dyspnoea and wheezing? https://bit.ly/3bLgw2A
A 57-year-old Portuguese woman was referred to 
our hospital for a second opinion due to multiple 
respiratory infections in the previous year with a 
recent onset of progressive dyspnoea and wheezing. 
She indicated there had been no weight loss during 
this period. She was a former smoker of 15 pack-
years who quit 20 years ago. The patient had a 
medical history of atrial fibrillation and breast 
cancer that was treated with radiotherapy. These 
both occurred in the same year, 5 years prior. 
Moreover, the patient specified that she had 
“asthma-like” symptoms during childhood. The 
patient was working as a lawyer and was medicated 
with bisoprolol 5 mg and montelukast 10 mg, both 
medications once a day. On examination, wheezes 
were auscultated in all lung fields, especially in the 
right upper lobe. Her oxygen saturation was 96% 
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Task 1
What would be your next approach?
a) Initiate oral corticosteroids
b) Initiate bronchodilator therapy
c) Request blood and functional lung tests
d) Request a computed tomography (CT) scan
Figure 1 Posteroanterior chest radiograph.
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We performed a functional lung test and 
no obstruction was found, despite a positive 
bronchodilator response with a ratio of forced 
expiratory volume in 1 s (FEV1)/forced vital 
capacity (FVC) of 74.25, FVC of 2.49 L (80.3%) 
and FEV1 of 1.95 L (73.8%) (which increased to 
2.33 L (88.4%) after bronchodilation challenge 
with 400 μg of salbutamol). The blood tests were 
normal. She was initiated on inhaled fluticasone 
furoate plus vilanterol (200/25 μg) once a day. On 
our follow-up, 1 month after our first consultation, 
the patient demonstrated only a slight improvement 
in dyspnoea, and wheezes were still detected in 
all lung fields. Another trial was made, this time 
with budesonide and formoterol (160/4.5 μg), 
twice a day, with the same poor outcome. The 
patient presented symptom relief from a 5-day 
trial of prednisolone 40 mg. Further investigation 
was undertaken in order to clarify the poor clinical 
response to bronchodilation despite the good 
results found in the functional lung test. Her 
thoracic CT scan can be seen in figure 2.
Task 2
Based on the history and chest CT scan, 
which of the following diagnoses would you 
investigate?
a) Allergic bronchopulmonary aspergillosis 
(ABPA)
b) Tracheobronchial amyloidosis (TBA)
c) Tracheobronchopathia 
osteochondroplastica




Figure 2 CT scan with a) narrowing of the lumina of the trachea, b) narrowing of the right upper lobe entrance, and c) calcified “finger-in-glove opacities” pattern.
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The CT scan demonstrated cylindrical and 
varicose bronchiectasis in the right upper lobe, 
filled with mucoid impaction and a “finger-in-
glove opacities” pattern with diffuse calcifications. 
These CT scan findings, combined with the patient’s 
history of recurring infections, wheeze and a good 
response to corticosteroids, were suggestive of 
ABPA. The CT scan also revealed diffused bronchial 
thickening mainly in the right upper lobe and in the 
anterior upper third of the trachea, so the differential 
diagnoses of TBA and tracheobronchopathia 
osteochondroplastica were also considered.Answer 2
d.
Task 3
What would be your next step in the 
investigation of ABPA?
a) Specific blood test plus prick test
b) Bronchoscopy
c) Initiate corticosteroid
d) Initiate corticosteroid plus antifungal 
medication
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There is a lack of consensus on the minimum 
criteria, either major or minor, required for the 
diagnosis of ABPA. To overcome this issue, the 
International Society for Human and Animal 
Mycology (ISHAM) established a working group in 
2011. This group has proposed revised criteria for the 
diagnosis of ABPA and recognised bronchial asthma 
and cystic fibrosis as predisposing conditions. The 
two obligatory criteria are 1) a positive immediate 
(type I) cutaneous hypersensitivity to Aspergillus 
antigen or elevated IgE levels against Aspergillus 
fumigatus, and 2) elevated total IgE levels 
(>1000 IU·mL−1). Both criteria should be present to 
make an ABPA diagnosis. The minor criteria include 
at least two out of the following three: 1) presence 
of precipitating or IgG antibodies to A. fumigatus, 
2) radiographic features in the lungs consistent 
with ABPA, and 3) peripheral blood eosinophilia 
(>500 cells·μL−1) in a steroid naïve patient [1, 2].
The role of A. fumigatus real-time PCR in 
bronchoalveolar lavage is still unclear. In our patient, 
total IgE blood levels were normal and antigen 
plus “prick test” for A. fumigatus was negative. 
Thus, we excluded the diagnosis of ABPA. To 
proceed with the investigation of the differential 
diagnoses proposed (TBA and tracheobronchopathia 
osteochondroplastica) a bronchofibroscopy was 
performed (figure 3). The examination showed 
deposits of a yellow material in the anterior wall of 
the trachea, mainly in the upper third. The same 
yellow material was found scattered along the 
airways, causing obstruction of the lumen in the 
right upper lobe entrance. Bronchoalveolar lavage 
was sent to bacterial, mycobacterial and mycological 
culture. All were negative. The tracheobronchial 
biopsy revealed infiltration of the submucosa with 
an amorphous hyaline material.
Task 4
In order to complete the diagnosis, which 









Figure 3 a) Infiltration of the trachea submucosa with yellow material and b) obstruction of the 
right upper lobe entrance with the same material.
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Congo red-stained slides demonstrated 
amyloid deposits (figure 4). An extensive workup 
was made to rule out systemic amyloidosis. 
First, the echocardiogram showed no signs of 
infiltrative disease and no other organ dysfunction 
was found, besides the lungs. Secondly, serum 
protein electrophoresis with immunofixation 
electrophoresis (IFE) and a 24-h urine collection 
with urine protein electrophoresis and IFE were 
normal. Finally, a bone marrow biopsy and 
myelogram showed no evidence of amyloidosis. 
These findings were discussed in a multidisciplinary 
meeting between an internist, a pulmonologist and 
a haematologist, and the patient was diagnosed 
with primary localised TBA.
The patient underwent bronchoscopic debulking 
and endobronchial ablation by neodymium-doped 
yttrium aluminium garnet (Nd:YAG) laser. Major 
amyloid plaques in the trachea were removed. 
Due to location with difficult access for a rigid 
bronchoscope, the lesions at the right upper lobe 
entrance were just partially treated. The patient 
also started on high doses of budesonide and 
formoterol inhaled therapy. 1 month after the 
intervention, the patient exhibited improvement 
and functional testing revealed an improvement 
in basal FEV1 results to 2.15 L (82.2%).
After 1 year of close outpatient follow-up with 
routine bronchoscopies, the patient remains with 
minor symptoms, controlled only with inhaled 
therapy, and there has been no need for further 
oral corticosteroids.
Discussion
Amyloidosis is characterised by the deposition in 
extracellular and/or intracellular tissues of abnormal 
proteins in a fibrillar form: the amyloid. These amyloid 
deposits may cause organ dysfunction [3]. Amyloidosis 
can be acquired or hereditary, primary or secondary, 
localised or systemic. The diagnosis of localised 
primary pulmonary amyloidosis is extremely rare 
and requires the exclusion of systemic amyloidosis, 
which accounts for up to 80% of pulmonary amyloid 
lesions. This form of lung amyloidosis may affect the 
parenchyma either as a diffuse, interstitial or nodular 
pattern; the tracheobronchial tree with submucosal 
plaques, as in our case; or as luminal tumour-like 
masses [4]. Although a rare disorder, primary TBA 
is the most common localised form of respiratory 
amyloidosis. According to the literature, only 0.5% of 
all symptomatic tracheobronchial lesions are amyloid 
lesions [3].
Patients with TBA can be asymptomatic or 
present with symptoms like progressive dyspnoea, 
cough and wheezing, mimicking other respiratory 
conditions [5, 6]. This can delay the diagnosis 
and/or lead to misdiagnosis with other common 
conditions like asthma or pneumonia. Patients 
with upper tracheal disease may develop upper 
airway obstruction, while distal tracheal or main 
bronchial disease may cause lobar collapse or 
recurrent airway and parenchymal infections [5]. 
Our patient had both upper and distal disease, 
which helps to explain her initial complaints of 
progressive dyspnoea, recurrent lung infections 
and wheezing.
Due to the high risk of developing airway 
obstruction with respiratory failure, the life 
expectancy for primary TBA is <10 years, with 




Which treatment would you consider?
a) Conservative treatment with close 
monitoring
b) Oral colchicine
c) Prednisone and melphalan
d) Bronchoscopic debulking and laser ablation
Answer 5
d.
Figure 4 Benign bronchial mucosa with deposition of 
amorphous hyaline material that stains with Congo red, 
compatible with amyloidosis.
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These data underscore the importance of an 
early diagnosis. In individuals with amyloidosis, 
a CT scan can reveal smooth or irregular nodular 
thickening of the tracheal wall and bronchi, 
which can be accompanied by calcified nodules 
in the submucosa. Therefore, a chest CT scan has 
proven to be the imaging examination of choice 
for the evaluation of TBA. As illustrated in this 
case, the chest radiograph can be normal. The 
differential diagnoses of diffuse tracheobronchial 
diseases include granulomatosis with polyangiitis, 
tracheobronchial papillomatosis, infectious 
involvement, relapsing polychondritis and 
tracheopathia osteochondroplastica (table 1) [8, 9].
Currently, there is no established treatment for 
endobronchial amyloidosis and clinical trials are 
needed. Treatment depends upon the patient’s 
symptoms and degree of obstruction. For patients 
who are symptomatic due to airway obstruction, 
bronchoscopic debulking and laser ablation are 
the mainstay of treatment [10]. Amyloid lesions 
are sensitive to laser photocoagulation. Carbon 
dioxide laser therapy is usually preferred in upper 
lesions (supraglottic and glottic), while Nd:YAG is 
indicated for tracheobronchial deposits.
External beam radiotherapy (EBRT) has been 
used in a few cases of endobronchial amyloidosis 
with success. The rationale for this therapy is that 
plasma cells producing amyloid protein seem to be 
photosensitive. EBRT could be useful in patients 
not suitable for bronchoscopic intervention. 
Cryotherapy has also been used, with a successful 
result in one case [3].
As far as pharmacological options are concerned, 
oral colchicine, along with prednisone and 
melphalan, are usually preferred for the treatment 
of systemic amyloidosis. Colchicine inhibits the 
microtubular system during the metaphase and 
decreases monocyte and neutrophil chemotaxis 
creating an anti-inflammatory effect. Unfortunately, 
there is a difference in the pathogenesis of systemic 
and local amyloidosis, and the good results with 
systemic disease cannot be extrapolated to TBA 
treatment. Despite that, there are some case reports 
on the use of colchicine for the treatment of TBA 
with variable results. In 2016, Morales et al. [11] 
reported a successful case of TBA treated with 
colchicine alone.
Bronchodilation therapy is used off label in 
some cases [3], with the assumption that a local 
bronchodilation action will reduce stenosis caused 
by amyloid plaques and provide symptom relief. 
This effect can be seen in the functional lung 
tests performed by our patient, with a positive 
bronchodilator response to salbutamol. We added 
inhaled corticosteroid (budesonide) to a long-acting 
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β2-agonist (formoterol), with the intention of adding 
an anti-inflammatory local action in addition to 
bronchodilation to overcome the partial stenosis 
that remained, after intervention, in the right upper 
lobe entrance. More studies are required to establish 
an efficient pharmacological approach to TBA.
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